BHI Therapeutic Sciences studies are registered at the clinical trial registries
Clinical trials are research investigations that play an important role in the development of health information and research for public health care. Clinical trials guiding principles are based on maximum benefit and minimal risk to the participants enrolled in a study. According to the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association Declaration of Helsinki), “every clinical trial must be registered in a publicly accessible database before recruitment of first subject”. The main registry...
read moreBHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE
BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin. Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look...
read moreBHI Therapeutic Sciences Inc. Notified by FDA that is can proceed with New Drug Clinical Trial for Acute Ischemic Stroke
BHI Therapeutic Sciences (BHITS), a leader in stem cell therapy and research utilizing human umbilical cord blood, announced today that the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application to allow for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed. Phase 1/2 Study entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic...
read moreProfessional Physique Champion is named Ambassador for BHI Slovakia.
Anton Antipov, an International Federation of Body Building and Fitness (IFBB) professional physique champion and fitness model, recently visited BHI Slovakia, stem cell research and treatment center, where he was named an ambassador for the healthcare organization. Mr. Antipov is an accomplished competitor and New York-based model, who has made a name for himself on social media and in the fitness industry. Growing up in Belarus, Mr. Antipov never had access to a gym, but he played sports to stay fit. After his family immigrated to America...
read moreStem Cells: The Next Frontier documentary screening for investors in NYC.
BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe. “At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe...
read moreBHI Therapeutic Sciences attended the World Economic Forum in Davos, Switzerland.
The 2018 World Economic Forum (WEF) in Davos explored the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology. During the past few days, the US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; and Manuel McDonald,...
read moreWORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 48TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS
FOUNDER OF BLUE HORIZON INTERNATIONAL AVAILABLE TO DISCUSS BREAKTHROUGHS IN STEM CELL RESEARCH ZURICH, Switzerland – January 18, 2017 – Dr. Brian Mehling, world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending The 48th Annual World Economic Forum (WEF) in DAVOS from January 23-26. This will be Dr. Mehling’s sixth year attending the global conference. The theme of this year’s forum is “Creating a Shared Future in a Fractured...
read moreBrian Mehling, M.D. and Blue Horizon International team to attend 3 Day Masterclass in Clinical Trials in New York
The 3 day long Masterclass in Clinical Trials and Medicine Development is organized by Terrapinn Ltd and will be held during February 22 – 24, 2017 in New York, NY. The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated health within the process of diffusion of new medical interventions, from pharmaceuticals, medical...
read moreBlue Horizon International making a splash at film festivals worldwide
Brian Mehling, M.D. and Blue Horizon International (BHI) have recently been making headlines – from being featured in VOGUE magazine, news of the preview screening of their stem cell documentary “Stem Cells – The Next Frontier,” which was screened during the Tribeca Film Festival in April, to its screening at the Cannes Film Festival on May 25th. There was also a well-attended networking event that followed the next day to celebrate the successful screening in Cannes. “Stem Cells – The Next Frontier” is a documentary about stem...
read moreBlue Horizon International team to attend Clinical Trials Masterclass in New York
Blue Horizon International team to attend Clinical Trials Masterclass in New York Brian Mehling, M.D. and Marina Manvelyan, Ph.D., will attend a three-day long Masterclass in Clinical Trials and Medicine Development from February 22 – 24, 2017 in New York, NY. The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated...
read more
